Size: | Price | Quantity | |
---|---|---|---|
50 mg | $54.00 | ||
250 mg | $180.00 |
Rasagiline mesylate (161735-79-1) is a potent, irreversible monoamine oxidase (MAO) inhibitor selective for MAO-B (IC50=4.43 nM) over MAO-A (IC50=412 nM).1 Parkinson’s disease therapeutic.2 Displays neuroprotective and neurorestorative properties in a Parkinson’s disease zebrafish model.3 Prevents α-synuclein-induced dopaminergic neuronal death and rescues TrkB neurotrophic signaling.4 Enhances BDNF levels and is neuroprotective in Parkinson’s disease models.5
References/Citations:
1) Youdim et al. (2001), Rasagiline [N-propargyl-1R(+)-aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B; Br. J. Pharmacol., 132 500
2) Cereda et al. (2017), Efficacy of rasagiline and selegiline in Parkinson’s disease: a head-to-head 3-year retrospective case-control study; J. Neurol., 264 1254
3) Cronin and Grealy (2017), Neuroprotective and Neuro-restorative Effects of Minocycline and Rasagiline in Zebrafish 6-Hydroxydopamine Model of Parkinson’s Disease; Neuroscience, 367 34
4) Kang et al. (2017), TrkB neurotrophic activities are blocked by α-synuclein, triggering dopaminergic cell death in Parkinson’s disease; Proc. Natl. Acad. Sci. USA, 114 10773
5) Ledreux et al. (2016), BDNF levels are increased by aminoindan and rasagiline in a double lesion model of Parkinson’s disease; Brain Res., 1631 34
Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary applications. Please note that we do not sell to individuals and that all orders placed by non-research organizations will incur a $20 restocking/refund fee
Rasagiline mesylate (161735-79-1) is a potent, irreversible monoamine oxidase (MAO) inhibitor selective for MAO-B (IC50=4.43 nM) over MAO-A (IC50=412 nM).1 Parkinson’s disease therapeutic.2 Displays neuroprotective and neurorestorative properties in a Parkinson’s disease zebrafish model.3 Prevents α-synuclein-induced dopaminergic neuronal death and rescues TrkB neurotrophic signaling.4 Enhances BDNF levels and is neuroprotective in Parkinson’s disease models.5
References/Citations:
1) Youdim et al. (2001), Rasagiline [N-propargyl-1R(+)-aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B; Br. J. Pharmacol., 132 500
2) Cereda et al. (2017), Efficacy of rasagiline and selegiline in Parkinson’s disease: a head-to-head 3-year retrospective case-control study; J. Neurol., 264 1254
3) Cronin and Grealy (2017), Neuroprotective and Neuro-restorative Effects of Minocycline and Rasagiline in Zebrafish 6-Hydroxydopamine Model of Parkinson’s Disease; Neuroscience, 367 34
4) Kang et al. (2017), TrkB neurotrophic activities are blocked by α-synuclein, triggering dopaminergic cell death in Parkinson’s disease; Proc. Natl. Acad. Sci. USA, 114 10773
5) Ledreux et al. (2016), BDNF levels are increased by aminoindan and rasagiline in a double lesion model of Parkinson’s disease; Brain Res., 1631 34
Calculate the molar concentration, mass or volume in a solution.
Concentration × Volume × Molecular Weight = Mass
For Postdoc
Customers!
Website Created by Advanta Advertising LLC.